Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: The disclosure relates to methods for treating cancer comprising determining certain patient biomarker levels prior to treatment.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: The invention relates to epitopes of SEMA4D and to binding agents, such as antibodies, that specifically bind to SEMA4D.

Abstract: Isolated polynucleotides are provided which encode antibody VH and VL polypeptides, and anti-CD100 antibodies and antigen-binding fragments thereof. In another aspect, the invention provides a vector comprising a polynucleotide of the invention. In another aspect, the invention provides a host cell comprising the vector of the invention. In another aspect, the invention provides a method of producing an antibody of the invention, e.g., for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen or a CD100 antigen located on the surface of a human CD100-expressing cell, wherein the antibody has CD100 blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen or a CD100 antigen located on the surface of a human CD100-expressing cell, wherein the antibody has CD100 blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies.

Abstract: A thermal printer (10) is useful for printing onto a receiver sheet (22, 24, 26) having a leading edge and a trailing edge and includes an elongated rotatable platen (34); an elongated thermal print head (30) positioned parallel to the platen; a closed loop pathway (12, 14, 16) for recirculating the receiver sheet in a printing direction from the platen and back to the platen, the platen being positioned for rotation in the printing direction with at least a portion of the platen in the pathway to engage the receiver sheet or a dye donor web (31); a supply roll (28) of dye donor web positioned upstream of the print head; a mechanism (76-112, 132-142) for moving the print head into the pathway opposite the platen to press the print head into engagement with the dye donor web, the dye donor web into engagement with the receiver sheet, and the receiver sheet into engagement with the platen; a mechanism (180-188) for rotating the platen in the printing direction to move either the dye donor web or both the dye do

Abstract: A thermal printer (10) is useful for printing onto a receiver sheet (22, 24, 26) and includes an elongated rotatable platen (34); an elongated thermal print head (30) positioned parallel to the platen; a supply roll (28) of dye donor web (31) positioned upstream of the print head; a mechanism (76-112, 132-142) for pressing the print head into engagement with the dye donor web and, in an absence of a receiver sheet, for pressing the dye donor web into engagement with the platen; and a mechanism (180-188) for rotating the platen, while the print head is pressing the dye donor web against the platen, to move the dye donor web between the print head and the platen.

Abstract: A thermal printer (10) is useful for printing onto a receiver sheet (22, 24, 26) having a leading edge and a trailing edge and includes an elongated rotatable platen (34); an elongated thermal print head (30) positioned parallel to the platen; a pathway (12, 14, 16) for receiving a receiver sheet in a printing direction from the platen, the platen being positioned for rotation in the printing direction with at least a portion of the platen in the pathway to engage a receiver sheet or a dye donor web (31); a supply roll (28) of dye donor web positioned upstream of the print head; a mechanism (76-112, 132-142) for moving the print head into the pathway opposite the portion of the platen to press the print head into engagement with the dye donor web, the dye donor web into engagement with the receiver sheet, and the receiver sheet into engagement with the platen; a mechanism (180-188) for rotating the platen in the printing direction to move either the dye donor web or both the dye donor web and the receiver she